Failed trials of vibostolimab and domvanalimab will be unveiled at SITC late-breakers.

After beating "historical" Xtandi masofaniten fails to beat actual Xtandi.

October's US approvals included Scemblix, Vyloy and Itovebi, while Lumakras was delayed.

The group goes after a KRAS-related target on which Boehringer recently gave up.

Conferences ramp up, and ASH abstracts near.

Pelabresib is delayed, and Novartis writes off $800m of the €2.7bn purchase.